Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-23
2006-05-23
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S616000
Reexamination Certificate
active
07049328
ABSTRACT:
A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
REFERENCES:
patent: 5922761 (1999-07-01), Lai
Medline Abstract, PubMed ID: 9350180, Hoffbrand, et al. , Journ. International Med. Suppl, (1997) 740 37-41.
Medline Abstract, PubMed ID: 9414297, Hoffbrand et al., Blood, (Jan. 1, 1998), 91(1), 295-300.
Medline Abstract, PubMed ID: 158721, Olivieri et al., Blood, (May 15, 1992), 79 (10), 2741-8.
Anderson, Lisa J, et al., Comparison of effects of oral deferiprone and subcutaneous desferrioxamine . . . in beta-thalassaemia: Lancet 2002; 360: pp. 516-520.
Black's Law Dictionary, p. 1502.
Butler, Craig, New YorkAcademy of Sciences Symposium, The Eighth Cooley's Anemia Symposium . . . for medical professionals and patients; CAF Website; May 17, 2005.
U.S. Newswire, Cooley's Anemia Foundation Presents Symposium on Iron Overload and Cardiac Disease: New Interventions: Dec. 10, 2004.
Barnabee et al., Deferiprone Protects Against Doxorubicin-Induced Myocyte Cytotoxicity, Free Radical Biology & Medicine 2002; vol. 33, No. 2: pp. 266-275.
Hasinoff et al., The Oral Iron Chelator ICL670A (Deferasirox) Does Not Protect Myocytes Against Doxorubicin, Free Radical Biology & Medicine 2003; vol. 35, No. 11: p. 1469-1479.
Gabutti V, Piga A. Results of Long-Term Iron-Chelating Therapy. Acta Haematol 1996; 95:26-36.
Wolfe LC, Olivieri NF, Sallan D, Colan S, Rose V, Propper RD et al. Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassemia major. N Engl J Med 1985; 312(25): 1600-1603.
Aldouri MA, Wonke B. Hoffbrand AV, Flynn DM, Ward SE, Agnew JE et al. High Incidence of Cardiomyopathy in Beta-Thalassemia Patients Receiving Regular Transfusion and Iron Chelation: Reversal by Intensified Chelation. Acta Haematol 1990; 84:113-117.
Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE et al. Efficacy of Desferrioxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. N Engl J Med 1994; 331(9):567-573.
Giardina PJV, Ehlers KH, Engle MA, Grady RW, Hilgartner MW. The Effect of Subcutaneous Desferrioxamine on the Cardiac Profile of Thalassemia Major: A Five-Year Study. Ann N Y Acad Sci 1985; 445:282-292.
Borgna-Pignatti C, Rugologgo S, DeStefano P, Piga A, et al. Survival and Disease Complications in Thalassemia Major. Ann N Y Acad Sci 1998; 850:227-231.
Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu P, McGee A et al. Survival in Medically Treated Patients with Homozygous Beta-Thalassemia. N Engl J Med 1994; 331(9):574-578.
Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (Deferiprone). Eur J Clin Pharmacol 1999; 55:1-6.
Grady RW, Hilgartner MW, Giardina PJV. Deferiprone: Its Effectiveness Relative to that of Desferrioxamine. 6thInternational Conference on Thalassemia and the Haemoglobinopathies, Abstract #2. 1997.
Olivieri NF, Brittenham GM, Armstrong SAM, Basran RK, Daneman R, Daneman N et al. First Prospective Randomized Trial of the Iron Chelators Deferiprone (Deferiprone) and Deferoxamine. Blood 86[10 Suppl. 1], 249a. 1995.
Olivieri NF, Belluzzo N, Muraca M, MacKenzie CC, Milone S, Polsinelli K et al. Evidence of Reduction in Hepatic, Cardiac and Pituitary Iron Stores in Patients with Thalassemia Major During Long-Term Therapy with the Orally Active Iron Chelating Agent Deferiprone. Blood 84[10 Suppl. 1], 109a. 1994.
Link G, Konijin AM, Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, desferrioxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J Lab Clin Med 1999; 133: 179-188.
De Franceschi L, Shalev O, Piga A, Collell M, Olivieri O, Corrocher R et al. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCI contransport activity. J Lab Clin Med 1999; 133:64-69.
Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JE. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypridinone iron chelator CP94. Biometals 1994; 7:267-271.
Hider RC, Kayyli R, Evans P, Mackinnon S. The production of Hydroxyl Radicals by Deferiprone—iron compounds under physiological conditions. Blood 94[10], 406a. 1999.
Engle MA, Erlandson M, Smith CH. Late Cardiac Complications of Chronic, Severe, Refractory Anemia with Hemochromatosis. Circulation 1964; 30:698-705.
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Disease of the heart and Great Vessels. 9thed. Boston, Mass; Little, Brown & Co; 1994:253-255.
Sirchia G, Zanella A. A Short Guide to the Management of Thalassemia. Thalassemia Today: the Mediterranean Experience. 1987: 635-670.
Berdoukas V, Bohans T. The Effect of Liver Iron on Cardiac Function. 10thInternational Conference on Oral Chelators in the treatment of Thalassemia and other diseases and Biomed Meeting 10, 13. 2000.
Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-Specific Serum Iron in Thalassemia: an Abnormal Serum Iron Fraction of Potential Toxicity. Br J Haematol 1978; 40: 255-263.
Olivieri NF, Koren G, Matsui D, Liu P, Blendis L, Cameron R et al. Reduction of Tissue Iron Stores and Normalization of Serum Ferritin During Treatment with the Oral Iron Chelator Deferiprone in Thalassemia Intermedia. Blood 1992; 79(10):2741-2748.
Al-Refaie FN, Sheppard L, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the Oral Iron Chelator Deferiprone (Deferiprone) in Patients with Iron Overload. Br J Haematol 1995; 89:403-408.
Novartis Marketing Brochure on Desferal (Desferrioxamine). 1998. Switzerland, Novartis Pharma AG.
Grady RW, Berdoukas VA, Rachmilewitz EA, Giardina PJ. Combining Deferiprone and Desferrioxamine to optimize Chelation. 10thInternational Conference on Oral Chelators in the treatment of Thalassemia and other diseases and Biomed Meeting, Limassol, Cyprus p. 9. Mar. 2000.
Töndury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br. J. Haematol. 1998;101(3):413-5.
Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339(7):417-423.
Hoffbrand AV, Al-Refaie FN, Davis B, Siritanakatkul N, Jackson BFA, Cochrane J et al. Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients. Blood 1998; 91(1):295-300.
Olivieri NF, Butany J, Templeton DM, Brittenham GM. Cardiac Failure and Myocardial Fibrosis in a patient with Thalassemia Major (TM) Treated with Long-Term Deferiprone. Blood 92[10 (Suppl 1)], 532a. 1998.
Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000; 108:305-312.
Agarwal MB, Rajadhyaksha G, Munot S. Deferiprone: A report of 22 patients who have taken it for over a decade. 10thInternational Conference on Oral chelators in the Treatment of Thalassemia and other Diseases and Biomed Meeting, Limassol, Cyprus, p. 3. Mar. 2000.
Liu P. Personal letter from Dr. Liu on reversal of the heart failure in a patient with thalassemia treated with deferiprone. May 13, 1996.
Ramm GA, Britton RS, Brunt EM, O'Neill R, Bacon BR. Hepatic iron overload in pathogen-free gerbils does not result in bridging fibrosis or cirrhosis. Bioiron'99, p. 327. 1999.
Hershko C., Link G., Konijn A. M. Relative effectiveness of desferrioxamine and deferiprone in protecting iron-loaded Gerbils from non-transferrin bound iron (NTBI) toxicity. Blood 94 (10): 422a; 1999.
Porter JB. Evaluation of New Iron Chelators for Clinical Use. Acta Haematol 1996; 95:13-25.
Al-Refaie FN, Hershko C, H
Piga Antonio
Spino Michael
Apotex Inc.
Henley III Raymond J.
Hughes Ivor M.
Hughes Neil H.
Sarkis Marcelo K.
LandOfFree
Use for deferiprone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use for deferiprone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use for deferiprone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543808